Induction of myelogenous leukemia cells with histone deacetylase inhibitors through down-regulating the Daxx protein expression

Abstract

The effects of two different histone deacetylase (HDAC) inhibitors, sodium butyrate (NaB) and trichostatin A (TSA),on apoptosis of human leukemic cells in vitro and the molecular mechanisms were investigated. The experiments were divided up 5 groups: control group, NaB group, TSA group, NaB+Z-VAD-FMK group and TSA+Z-VAD-FMK group. The apoptosis rate was determined by morphological analysis and flow cytomytry. The expression of Daxx, Bcl-2, and Bcl-xl proteins was detected by Western blot. NaB and TSA could induce the apoptosis of HL-60 and K562 cells, and Z-VAD-FMK caused a marked decrease in apoptosis induced by HDAC inhibitors. HDAC inhibitors could down-regulate the expression of Daxx protein, but had no significant influence on the expression of Bcl-2 and Bcl-xl proteins. The results suggested that NaB and TSA induce distinct caspase-dependent apoptosis of human leukemic cells through down-regulating the expression of Daxx protein in vitro.

Keywords

histone deacetylase inhibitors / apoptosis / leukemia / caspases / Daxx

References

[1] NishiokaC., IkezoeT., YangJ., et al.. Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell. Leukemia, 2008, 22(7): 1449-1452

[2] TsapisM., LiebM., ManzoF., et al.. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol, 2007, 39(7-8): 1500-1509

[3] KimB.S., BaeE., KimY.J., et al.. Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs, 2007, 18(6): 641-647

[4] SchmidtK., SeegerK., ScheibenbogenC., et al.. Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia. J Leukoc Biol, 2009, 85(3): 563-573

[5] WittichS., ScherfH., XieC., et al.. Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. Anticancer Drugs, 2005, 16(6): 635-643

[6] VranaJ.A., DeckerR.H., JohnsonC.R., et al.. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene, 1999, 18(50): 7016-7025

[7] LiQ., WangX., WuX., et al.. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res, 2007, 67(1): 66-74

[8] NishiokaC., IkezoeT., YangJ., et al.. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res, 2008, 32(9): 1382-1392

[9] BartoliniG., OrlandiM., PapiA., et al.. Growth inhibition and proapoptotic activity induction by IIF and valproic acid on RA-resistant leukemia cells. Anticancer Res, 2008, 28(1A): 283-288

[10] PetrellaA., D’AcuntoC.W., RodriquezM., et al.. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur J Cancer, 2008, 44(5): 740-749

[11] Garcia-ManeroG., AssoulineS., CortesJ., et al.. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood, 2008, 112(4): 981-989

[12] CarewJ.S., GilesF.J., NawrockiS.T.. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett, 2008, 269(1): 7-17

[13] RichonV.M., EmilianiS., VerdinE., et al.. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA, 1998, 95(6): 3003-3007

[14] RaffM.C.. Social controls on cell survival and cell death. Nature, 1992, 356(6368): 397-400

[15] Garcia-CalvoM., PetersonE.P., LeitingB., et al.. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem, 1998, 273(49): 32 608-32 613

[16] YangX., Khosravi-FarR., ChangH.Y., et al.. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell, 1997, 89(7): 1067-1076

[17] SalomoniP., KhelifiAF. D.. death or survival protein?. Trends Cell Biol, 2006, 16(2): 97-104

[18] VillungerA., HuangD.C., HollerN., et al.. Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD. J Immunol, 2000, 165(3): 1337-1343

[19] MichaelsonJ.S., BaderD., KuoF., et al.. Loss of Daxx, a promiscuously interacting protein, results in extensive apoptosis in early mouse development. Genes Dev, 1999, 13(15): 1918-1923

[20] KorsmeyerS.J.. BCL-2 gene family and the regulation of programmed cell death. Cancer Res, 1999, 59(Suppl7): 1693s-1700s